FDA Approves Ensitrelvir as First Oral Antiviral for COVID-19 Prevention

The U.S. Food and Drug Administration (FDA) has approved Shionogi’s ensitrelvir, marketed as Xocova, as the first oral antiviral for post-exposure prophylaxis in adults and adolescents aged 12 and older. This step follows the results of the Phase 3 SCORPIO-PEP trial, which showed a 67% reduction in the risk of developing symptomatic COVID-19 compared to a placebo group during the first ten days after exposure to the virus.

The availability of ensitrelvir offers a new way to manage COVID-19, particularly after a person has been exposed. While prevention has traditionally centered on vaccination and social distancing, an oral antiviral provides another layer of protection. The SCORPIO-PEP trial studied household contacts, focusing on those at higher risk of transmission in shared living spaces. The drug works by stopping the SARS-CoV-2 virus from replicating, which makes symptomatic infection less likely. This is particularly helpful for people who are unvaccinated or at a higher risk of becoming severely ill. Because the treatment is a simple pill, it is easier for patients to take, which helps with treatment consistency and makes antiviral care more accessible.

Adding ensitrelvir to the available treatments will likely have a broader impact on public health. By preventing symptoms from developing, the medication can help reduce the pressure on healthcare systems and lower the number of cases that lead to hospitalization. This is especially important as new variants of the virus appear, requiring more flexible approaches to treatment and prevention.

The approval of ensitrelvir also opens the door for further research into antiviral therapies. Future work may look at how effective the drug is against new variants and how it performs when used with other treatments. This move represents a proactive shift in managing the virus, contributing to the safety of both individuals and their communities.